WO2014203048A1 - Photocatalytic composition for environmental purification and method thereof - Google Patents
Photocatalytic composition for environmental purification and method thereof Download PDFInfo
- Publication number
- WO2014203048A1 WO2014203048A1 PCT/IB2014/000299 IB2014000299W WO2014203048A1 WO 2014203048 A1 WO2014203048 A1 WO 2014203048A1 IB 2014000299 W IB2014000299 W IB 2014000299W WO 2014203048 A1 WO2014203048 A1 WO 2014203048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- test
- range
- water
- virus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000007613 environmental effect Effects 0.000 title claims abstract description 29
- 238000000746 purification Methods 0.000 title claims description 6
- 230000001699 photocatalysis Effects 0.000 title description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 89
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims abstract description 34
- 229910052586 apatite Inorganic materials 0.000 claims abstract description 32
- 239000011941 photocatalyst Substances 0.000 claims abstract description 29
- 239000002250 absorbent Substances 0.000 claims abstract description 18
- 230000002745 absorbent Effects 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- 239000002265 redox agent Substances 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- 239000004408 titanium dioxide Substances 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims description 11
- 235000019980 sodium acid phosphate Nutrition 0.000 claims description 11
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 11
- 229940045872 sodium percarbonate Drugs 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 10
- 231100000331 toxic Toxicity 0.000 claims description 7
- 230000002588 toxic effect Effects 0.000 claims description 7
- 239000000383 hazardous chemical Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229910021536 Zeolite Inorganic materials 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- 229910052570 clay Inorganic materials 0.000 claims description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 3
- 239000010457 zeolite Substances 0.000 claims description 3
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005751 Copper oxide Substances 0.000 claims description 2
- 229910052589 chlorapatite Inorganic materials 0.000 claims description 2
- 229910000431 copper oxide Inorganic materials 0.000 claims description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 2
- 229940077441 fluorapatite Drugs 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- 229910001930 tungsten oxide Inorganic materials 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 238000005352 clarification Methods 0.000 abstract description 24
- 238000012360 testing method Methods 0.000 description 129
- 241000700605 Viruses Species 0.000 description 107
- 239000012085 test solution Substances 0.000 description 52
- 239000000523 sample Substances 0.000 description 49
- 239000000725 suspension Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 42
- 239000002609 medium Substances 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 26
- 239000008213 purified water Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 24
- 229910002092 carbon dioxide Inorganic materials 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000012488 sample solution Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 239000006143 cell culture medium Substances 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 18
- 206010015150 Erythema Diseases 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 238000003860 storage Methods 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 12
- 230000004660 morphological change Effects 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 230000005856 abnormality Effects 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 235000019645 odor Nutrition 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000186779 Listeria monocytogenes Species 0.000 description 6
- 231100000645 Reed–Muench method Toxicity 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000005723 virus inoculator Substances 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 206010015946 Eye irritation Diseases 0.000 description 4
- 241000714201 Feline calicivirus Species 0.000 description 4
- 241001263478 Norovirus Species 0.000 description 4
- 241001138501 Salmonella enterica Species 0.000 description 4
- 108010079723 Shiga Toxin Proteins 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000013 eye irritation Toxicity 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 3
- RODZIAKMFCIGPL-UHFFFAOYSA-N P.I.I Chemical compound P.I.I RODZIAKMFCIGPL-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000011151 fibre-reinforced plastic Substances 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 231100000944 irritant response Toxicity 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000709727 Human poliovirus 3 Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001397616 Influenza A virus (H1N1) Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 231100000694 OECD Guidelines for the Testing of Chemicals Toxicity 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000607361 Salmonella enterica subsp. enterica Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000012925 biological evaluation Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 208000013441 ocular lesion Diseases 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000581652 Hagenia abyssinica Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000826 nictitating membrane Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- -1 peroxide-epoxides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910052585 phosphate mineral Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000008842 sick building syndrome Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003403 water pollutant Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/39—Photocatalytic properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/34—Chemical or biological purification of waste gases
- B01D53/74—General processes for purification of waste gases; Apparatus or devices specially adapted therefor
- B01D53/86—Catalytic processes
- B01D53/8668—Removing organic compounds not provided for in B01D53/8603 - B01D53/8665
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/34—Chemical or biological purification of waste gases
- B01D53/74—General processes for purification of waste gases; Apparatus or devices specially adapted therefor
- B01D53/86—Catalytic processes
- B01D53/88—Handling or mounting catalysts
- B01D53/885—Devices in general for catalytic purification of waste gases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
- B01J21/063—Titanium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/16—Phosphorus; Compounds thereof containing oxygen, i.e. acids, anhydrides and their derivates with N, S, B or halogens without carriers or on carriers based on C, Si, Al or Zr; also salts of Si, Al and Zr
- B01J27/18—Phosphorus; Compounds thereof containing oxygen, i.e. acids, anhydrides and their derivates with N, S, B or halogens without carriers or on carriers based on C, Si, Al or Zr; also salts of Si, Al and Zr with metals other than Al or Zr
- B01J27/1802—Salts or mixtures of anhydrides with compounds of other metals than V, Nb, Ta, Cr, Mo, W, Mn, Tc, Re, e.g. phosphates, thiophosphates
- B01J27/1806—Salts or mixtures of anhydrides with compounds of other metals than V, Nb, Ta, Cr, Mo, W, Mn, Tc, Re, e.g. phosphates, thiophosphates with alkaline or alkaline earth metals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/14—Phosphorus; Compounds thereof
- B01J27/182—Phosphorus; Compounds thereof with silicon
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/20—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state
- B01J35/23—Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/04—Mixing
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0063—Photo- activating compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/12—Water-insoluble compounds
- C11D3/1213—Oxides or hydroxides, e.g. Al2O3, TiO2, CaO or Ca(OH)2
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/39—Organic or inorganic per-compounds
- C11D3/3942—Inorganic per-compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/02—Inorganic compounds
- C11D7/04—Water-soluble compounds
- C11D7/10—Salts
- C11D7/16—Phosphates including polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/02—Inorganic compounds
- C11D7/20—Water-insoluble oxides
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/265—Carboxylic acids or salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2253/00—Adsorbents used in seperation treatment of gases and vapours
- B01D2253/10—Inorganic adsorbents
- B01D2253/104—Alumina
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2253/00—Adsorbents used in seperation treatment of gases and vapours
- B01D2253/10—Inorganic adsorbents
- B01D2253/106—Silica or silicates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2253/00—Adsorbents used in seperation treatment of gases and vapours
- B01D2253/10—Inorganic adsorbents
- B01D2253/106—Silica or silicates
- B01D2253/108—Zeolites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2253/00—Adsorbents used in seperation treatment of gases and vapours
- B01D2253/10—Inorganic adsorbents
- B01D2253/106—Silica or silicates
- B01D2253/11—Clays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/10—Noble metals or compounds thereof
- B01D2255/104—Silver
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/20—Metals or compounds thereof
- B01D2255/204—Alkaline earth metals
- B01D2255/2047—Magnesium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/20—Metals or compounds thereof
- B01D2255/207—Transition metals
- B01D2255/20707—Titanium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/20—Metals or compounds thereof
- B01D2255/207—Transition metals
- B01D2255/20761—Copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/20—Metals or compounds thereof
- B01D2255/207—Transition metals
- B01D2255/20776—Tungsten
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2255/00—Catalysts
- B01D2255/20—Metals or compounds thereof
- B01D2255/207—Transition metals
- B01D2255/20792—Zinc
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2257/00—Components to be removed
- B01D2257/40—Nitrogen compounds
- B01D2257/406—Ammonia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2257/00—Components to be removed
- B01D2257/90—Odorous compounds not provided for in groups B01D2257/00 - B01D2257/708
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2257/00—Components to be removed
- B01D2257/91—Bacteria; Microorganisms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2258/00—Sources of waste gases
- B01D2258/02—Other waste gases
- B01D2258/0266—Other waste gases from animal farms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2258/00—Sources of waste gases
- B01D2258/02—Other waste gases
- B01D2258/0275—Other waste gases from food processing plants or kitchens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2258/00—Sources of waste gases
- B01D2258/06—Polluted air
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4508—Gas separation or purification devices adapted for specific applications for cleaning air in buildings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4533—Gas separation or purification devices adapted for specific applications for medical purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4566—Gas separation or purification devices adapted for specific applications for use in transportation means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/45—Gas separation or purification devices adapted for specific applications
- B01D2259/4566—Gas separation or purification devices adapted for specific applications for use in transportation means
- B01D2259/4575—Gas separation or purification devices adapted for specific applications for use in transportation means in aeroplanes or space ships
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2259/00—Type of treatment
- B01D2259/80—Employing electric, magnetic, electromagnetic or wave energy, or particle radiation
- B01D2259/802—Visible light
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/08—Heat treatment
Definitions
- the present disclosure relates to a composition which is used as an environmental purification material.
- the present disclosure further relates to a process for producing the composition.
- An absorbent or an acid or alkali solution has been widely used in many fields for preventing or removing malodors or for removing harmful substances in the air.
- One major problem associated with this method is the treatment of the waste solution or the adsorbent utilized, which may cause secondary pollution.
- a method to hide unpleasant odors by using a perfume may also be used, but there is a possibility that the odor of the perfume gets transferred to the food materials or substances and hence resulting in damage to the food by the smell of the perfume itself.
- organic chemical substances particularly based on alcohols, phenols, aldehydes, carboxylic acid, esters, ethers, nitriles, peroxide-epoxides, halogens, and organometals have long been used to inhibit the proliferation of microbes.
- these chemicals provide good antibacterial and bactericidal strength, they are essentially toxic, irritate the skin, and may lead to allergies, "sickhouse syndrome", "hypersensitivity to chemical substances, etc. Therefore, care must be taken in the use of these chemicals.
- US7375069 describes photocatalytic methods, compositions and kits for removal of stains such as oil, grease, paint, mold, rust and the like from solid surfaces.
- EP 1437397 describes a cleaning agent comprising diamond-like carbon, or a covered component produced by partially covering the surface of diamond-like carbon with a ceramic, a thickener and an oxidant.
- EP 1064999 discloses a photocatalytic powder for environmental clarification, comprising finely divided titanium dioxide having a coating of porous calcium phosphate, further calcium phosphate precipitated form pseudo substance solution consisting of sodium chloride, sodium phosphate, potassium chloride and so on.
- US6180548 discloses an environment purifying material wherein porous apatite film is clotted on the surface of titanium oxide which comprises a carrier selected from alumina, silica gel, zeolite, clay sintered.
- the apatite is obtained from pseudo-body fluid having composition ratio: Na + 120 to 160 mM, HP0 4 2" 0.5 to 30 mM.
- the present disclosure relates to a composition
- a composition comprising: a photocatalyst; a redox agent; an absorbent; a stabilizing agent, and water; wherein the photocatalyst is coated with apatite.
- the present disclosure further relates to a process for producing a composition, the process comprising heating 2%-8% w/w of a photocatalyst coated with apatite in a slurry comprising at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%- 1% w/w, a stabilizing agent in the range of 20%-25% w/w, and water in the range of 0.5%- 1% v/w to obtain the composition.
- composition disclosed in the present disclosure is used as an environmental purification material by dissolving toxic materials into non-hazardous materials.
- Figure 1 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is formaldehyde, in accordance with an embodiment of the present disclosure.
- Figure 2 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is acetaldehyde, in accordance with an embodiment of the present disclosure.
- Figure 3 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is ammonia, in accordance with an embodiment of the present disclosure.
- the present disclosure is to provide a composition for environmental clarification that has high dissolving capability, high absorption efficiency, improved safety and stability, and react with visible ray having low intensity.
- the present disclosure provides a composition
- a composition comprising: a photocatalyst; a redox agent; an absorbent; a stabilizing agent; and water; wherein the photocatalyst is coated with apatite.
- the present disclosure provides a composition
- a composition comprising: a photocatalyst in the range of 2%-8% w/w; a redox agent in the range of 40%-65% w/w; an absorbent in the range of 0.5%-l% w/w; a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%-l% v/w, wherein the photocatalyst is coated with apatite.
- the present disclosure provides a composition for environmental clarification comprising: 8% w/w of a photocatalyst; 65% w/w of at least one redox agent; 1 % w/w of an absorbent; 25% w/w of a stabilizing agent; and 1% v/w of water, wherein photocatalyst is coated with apatite.
- the photocatalyst used in the present disclosure is a substance that absorbs light and, in doing so, catalyzes a reaction.
- the photocatalyst of the present disclosure is selected from the group consisting of titanium dioxide, zinc oxide, tungsten oxide, silver oxide, copper oxide, and magnesium oxide.
- the preferred photocatalyst used in the present disclosure is titanium dioxide which is further coated with apatite.
- Photocatalytic action results when titanium oxide is irradiated with light, an electron having a strong reducing action and a positive hole having a strong oxidizing action are generated and a molecular seed coming into contact therewith is decomposed by the oxidation-reduction action.
- the average particle diameter of titanium dioxide is in the range of 20 nanometer to 500 nanometer.
- the preferred average diameter of titanium dioxide is in the range of 100 nanometer to 300 nanometer.
- the average particle diameter is smaller than 20 nanometer, the efficient production is difficult to attain, whereas if the average particle diameter exceeds 500 nanometer, the performance as a photocatalyst greatly decreases.
- the composition is mixed with water in a range of 1 :70 to 1 : 100 w/v.
- the aqueous composition of the photocatalyst composition is used in the application quantity range of 0.1 -1.5 % (w/v) with water.
- the apatite used in the present disclosure is selected from the group consisting of hydroxyapatite, fluorapatite, chlorapatite, and combinations thereof.
- the apatite of the present disclosure is a phosphate mineral used to coat the photocatalyst.
- the apatite of the present disclosure is in crystalline form. In general, apatite is used as a material for medical products and cosmetics, such as treatment for bone fracture and cavity.
- the preferred apatite used in the present disclosure is hydroxyapatite. Hydroxyapatite is used because of safety to human body and has excellent absorbance of ammonia and aldehyde.
- the photocatalyst coated with apatite can be produced by methods known in the art or can be purchased separately.
- the redox reagent of the present disclosure is selected from the group consisting of citric acid, sodium percarbonate and combinations thereof.
- the redox reagent used in the present disclosure is a reagent that can induce an oxidation or a reduction.
- the absorbent is selected from the group consisting of alumina, silica gel, zeolite, clay sintered compacts, glass and foam ceramics.
- the absorbent of the present disclosure is a substance that is capable of absorbing heat, light, moisture, etc.
- the preferred absorbent is silica gel.
- Silica gel is suitable for the coating by its transparency.
- the stabilizing agent of the present disclosure is sodium acid phosphate. Stabilizing agent is used in a very small amount to avoid the deterioration of its performance.
- composition of the present disclosure has an application in form of a paste, powder or slurry, preferably in form of a powder.
- the shelf life of the composition for environmental clarification of the present disclosure is 2-3 years.
- the storage conditions to maintain the performance of the composition of the present disclosure during shelf life is by avoiding moisture and direct sunlight from the composition, further avoid storage at room temperature or higher temperature.
- the temperature to store the composition is less than 10°C.
- the preferred temperature to store the composition is less than 5°C.
- the present disclosure provides a composition for environmental clarification comprising: titanium dioxide in the range of 6%-8% w/w; citric acid in the range of 20%- 30% w/w; sodium percarbonate in the range of 30%-35% w/w; silica gel in the range of 0.5%-l% w/w; sodium acid phosphate in the range of 20%-25% w/w; and water in the range of 0.5%- 1% v/w, wherein titanium dioxide is coated with apatite.
- the present disclosure provides a composition for environmental clarification comprising: 8% w/w of titanium dioxide; 30% w/w of citric acid; 35% w/w of sodium percarbonate; 1% w/w of silica gel; 25% w/w of sodium acid phosphate; and 1 % w/v of water, wherein titanium dioxide is coated with apatite.
- the composition for environmental clarification is active at an intensity of light in a range from 1/10 to 1/100 candela.
- the composition of the present disclosure reacts with visible ray having low intensity like light emitted from electric bulbs, room light to high energy ray like sunlight and generate high dissolving capability.
- a process for producing a composition comprising heating 2%-8% of a photocatalyst coated with apatite in a slurry containing at least one redox agent, an absorbent, a stabilizing agent, and water to obtain a composition.
- the process comprising heating 2%- 8% w/w of a photocatalyst coated with apatite in a slurry containing at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%- 1 % w/w, a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%-l% v/w to obtain a composition.
- the process comprising heating 6%- 8% w/w of a photocatalyst coated with apatite in a slurry containing at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%-l % w/w, a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%- 1 % v/w in the temperature at the range of 30-40 °C for 20-26 hours to obtain a composition.
- the process further comprises diluting the composition with water in a range of 1 : 70 to 1 : 100 w/v.
- composition disclosed in the present disclosure is used as an environmental purification material by dissolving toxic materials into non-hazardous materials like water and carbon dioxide gas.
- the composition for environmental clarification of the present disclosure is used to inactivate or eliminate micro-organisms, sterilize, deodorize sludge,
- the advantageous effect of the composition of the present disclosure includes (1) anti bacteria and anti fungus effect: dissolve and eliminate E. coli, Legionella, influenza, viruses, fungus, and other toxicity causing microorganisms in foods, (2) deodorization: dissolve viruses, bacteria, and toxic organic materials that cause bad odor into odor-free and non-hazardous water and carbon dioxide gas, and (3) sanitization of soil and water quality: sterilize, deodorize sludge, water pollutant with anaerobes and blue-green algae.
- the composition for environmental clarification of the present disclosure is applied by spray coating a 100-fold diluted solution by plating machine or by ultra sonic nebulizer.
- composition for environmental clarification of the present disclosure include hospital/operation room, hospital/examination room, waiting room, care home, kitchen/food processing plant, hotel, restaurant, vehicle, ship airplane, residence, chicken farm, dairy farm, risk management, and contingency planning.
- composition of the present disclosure is irradiated with light to generate hydroxyl radical (OH radical), whereby hydroxyl radical (OH radical) generated results in the conversion of toxic organic materials into non-hazardous materials.
- OH radical hydroxyl radical
- the mechanism of the composition for the purification of environment includes; irradiating the light on the composition for environmental clarification to generate hydroxyl radical (OH radical), due to the polarity of the .OH radical the dissolving capability of the composition for environmental clarification increases that results in the conversion of toxic organic materials into non- hazardous materials such as water and carbon dioxide.
- OH radical hydroxyl radical
- composition for environmental clarification comprises the following active ingredients: • titanium dioxide coated with apatite in the range of 2%-8% w/w;
- silica gel in the range of 0.5%-l% w/w;
- composition for environmental clarification comprises the following active ingredients:
- citric acid in the range of 20% -30% w/w
- silica gel in the range of 0.5%- 1 % w/w;
- composition for environmental clarification comprises the following active ingredients:
- composition was stored at temperature less than 10°C.
- composition was stored at temperature less than 10°C.
- Table 1 describes the comparison disclosed in the present disclosure with other methods such as ozone, hypochlorous acid, chrorine dioxide. It was observed from Table 1 that the composition disclosed in the present disclosure have higher anti-bacterial activity than other known methods.
- Table 1 Comparison of the activity of the composition with other methods.
- Suspension Solution of the composition for environmental clarification [0062] The suspending solution was prepared by homogenous mixing of composition for environmental clarification in water for 1-2 hours with constant stirring. The above mixture was degassed for 1 day under an inert atmosphere. The resulting mixture was kept under constant stirring for 2-3 minutes to obtain the suspending solution of the composition for environmental clarification in water.
- test sample was dissolved in water to make 1 w/v% test solution.
- 1 w/v% test solution was diluted with water for injection to make 100 mg/mL test dilution.
- mice Female mice, at an age of 5 weeks were tested. Before test, they are acclimated to laboratory conditions for about 1 week to verify that no abnormalities are shown in general conditions. They were hosted in plastic cages (five animals per cage) under standard laboratory conditions (temperature 23 °C ⁇ 2 °C, light dark cycle: 12/12 hours). Feed (Labo MR Stock diet, Nihon Nosankogyo K.K) and tap water were provided ad libitum throughout the experiment.
- the values are mean ⁇ SD.
- Both the eyes of each animal are examined on the first day of the test to ensure the absence of any ocular abnormalities. After the animals are weighed, 0.1 g / 0.1 mL of the test sample is instilled into the conjunctival sac of one eye of each animal. The lids are then gently held together for about 1 second. Similarly, water for injection, as vehicle control, was instilled into another eye. Then, the cornea, iris, and conjunctivae are observed clinically using a hand slit-lamp at 1, 24, 48 and 72 hours after the instillation. The ocular reactions are observed and scored according to the criteria of the Draize method, shown in Table 4.
- the corneal epithelium is examined further in detail with the use of fluorescein sodium at each observation time except for 1 hour after the instillation. Other eyes, which are not treated with the test sample, are used as controls.
- the total score was calculated for each animal according to the formula shown in Table 5, and the mean total score is obtained at each observation time. Eye irritation potential of 1 w/v% test sample was graded by means of the maximum mean total score on the basis of Table 6.
- test sample was tested for eye irritation potential in rabbits in accordance with OECD Guidelines for the Testing of Chemicals 405 (201 2).
- Redness refers to palpebral and bulbar conjunctivae excluding cornea and iris
- lids 2 just adjacent to lids 2 Discharge with moistening of the lids and hairs,
- A, B, and C show the scores of (A), (B), and (C) given in Table 5, respectively.
- Score (l) A x B x 5 0(0) 0(0) 0(0) 0(0) 0(0)
- Score (2) A x 5 0(0) 0(0) 0(0) 0(0)
- Score (3) (A + B + C) * 2 0(0) 0(0) 0(0) 0(0)
- Table 1 1 Scores of irritant response in the rabbit No. 3
- test sample is dissolved / suspended / diluted in water for injection to make 1 w/v% test solution.
- the patches were covered with Blenderm surgical tape.
- the other intact and abraded sections served as controls.
- all the test sections are wiped with water for injection to remove the test solutions.
- the skin reactions are read at 1 , 24, 48 and 72 hours after removal of 1 w/v% test solution according to the criteria shown in Table 12.
- the P.I.I was calculated according to ISO 10993-10 Biological Evaluation of Medical Devices-Part 10 (2010).
- the scores of the readings at 24, 48 and 72 hours were added together and divided by 6.
- the mean value of three animals is regarded as P.I.I.
- the degree of the primary skin irritation was evaluated in accordance with the criteria shown in Table 13. The animals are weighed at the start and completion of the test.
- the test sample was tested for primary skin irritation in rabbits in accordance with OECD Guidelines for the Testing of Chemicals 404 (2002).
- 1 w/v% test solution was applied occlusively for 4 hours to the intact and abraded skin.
- the primary irritation index (P.I.I.) calculated according to ISO 10993-10 Biological Evaluation of Medical Devices-Part 10 (2010) was 0.2. Consequently, the primary skin irritation of 1 w/v% test solution is considered to be negligible.
- Severe edema (raised more than 1 mm
- the sample solution was mixed with Poliovirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test.
- results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 100- fold with a cell support medium.
- Test cell HEp-2 cells: HEp-2 ATCC CCL-23 (Dainippon Pharmaceutical Co. Ltd.)
- Cell culture medium Eagle's MEM "Nissui"(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
- Cell support medium Eagle's MEM “Nissui"(l ) including 2 % of fetal bovine serum.
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5%) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 0.3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 ml, of 0.3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 100-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After removal of the culture medium, 0.1 mL of the cell support medium was added. Next, 100-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then, 0.1 mL of each dilution was poured into four wells each and cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days.
- C0 2 incubator C0 2 : 5 %
- TCID 50 median tissue culture infectious dose
- the sample solution was mixed with Poliovinis suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test.
- Test cell HEp-2 cells: HEp-2 ATCC CCL-23 (Dainippon Pharmaceutical Co. Ltd.)
- Cell culture medium Eagle's MEM “Nissui”(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
- Cell support medium Eagle's MEM “Nissui”(l) including 2 % of fetal bovine serum.
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 0.1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 ml, of 0.1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 100-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After removal of the culture medium, 0.1 mL of the cell support medium was added. Next, 100-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then, 0.1 mL of each dilution was poured into four wells each and cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days.
- C0 2 incubator C0 2 : 5 %
- Example 14 After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cytopathic effects) had occurred. Then, median tissue culture infectious dose (TCID 50 ) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
- TCID 50 median tissue culture infectious dose
- the sample solution was mixed with Feline calicivirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test. Feline calicivirus is a commonly used as a surrogate for Norovirus, which can not been cultured routinely.
- results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 10000-fold with a cell support medium.
- Test virus Feline calicivims F-9 ATCC VR-782
- Test cell CRFK cells (Dainippon Pharmaceutical Co., Ltd.) [00107] (3) Culture media
- Cell culture medium Eagle's MEM "Nissui"(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed w i th an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase- contrast microscope to observe if any morphological changes (cylopathic effects) had occurred. Then, median tissue culture infectious dose (TCID 50 ) was calculated by Reed- Muench method and converted into virus infectivity liter per 1 mL of the mixture.
- TCID 50 median tissue culture infectious dose
- the sample solution was mixed with Feline calicivirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test. Feline calicivirus is a commonly used as a surrogate for Norovirus, which can not been cultured routinely.
- Test virus Feline calicivims F-9 ATCC VR-782
- Test cell CRFK cells (Dainippon Pharmaceutical Co., Ltd.)
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000- fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold diluti on of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days.
- TCID 50 median tissue culture infectious dose
- the sample solution was mixed with Influenza virus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test.
- TCID50 Median tissue culture infectious dose
- Test virus Influenza A virus (H1N1)
- Test cell MDCK (NBL-2) cells ATCC CCL-34 strain (Dainippon Pharmaceutical Co., Ltd.)
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000- fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each di lution was poured into four wells each and cultured in a CO; incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days.
- the sample solution was mixed with Influenza virus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test.
- TCID 50 IV edian tissue culture infectious dose
- Test virus Influenza A virus (H1N1)
- Test cell MDCK (NBL-2) cells ATCC CCL-34 strain (Dainippon Pharmaceutical Co., Ltd.)
- test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
- Virus inoculation After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C0 2 incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 1 to 5 days.
- c) Preparation of virus suspension The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
- Test procedure The sample was dissolved in purified water to make 1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
- [00135] (6) Virus infectivity assay The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C0 2 : 5 %) at 37 °C ⁇ 1 °C for 4 to 7 days.
- Suspensions of Escherichia coli, Escherichia coli (Serovar 0157:H7, Shiga toxin I & Il-producing Escherichia coli), Listeria monocytogenes, Salmonella enterica, and Methicillin-resistant Staphylococcus aureus (MRSA) were separately inoculated to the sample (hereafter called “the test solutions") and stored at room temperature. After 30 minutes and also after 6 hours, the viable cell count of each test solution was determined. The test method for determining viable cell count was validated by a preliminary test.
- Table 22 shows the results.
- the results of the preliminary test revealed that the test solution should be diluted by 10-fold [for Escherichia coli (Serovar 0157:H7)], by 100-fold (for Escherichia coli) and by 1000-fold (for Listeria monocytogenes, Salmonella enterica, and MRSA) with SCDLP broth to remove the effects of the sample.
- Test strains (a) Escherichia coli NBRC 3972, (b) Escherichia coli ATCC 43895 (Serovar 0157:H7, Shiga toxin I & 11-producing Escherichia coli), (c) Listeria monocytogenes VTU 206, (d) Salmonella enterica subsp. enterica NBRC 3313, (e) Staphylococcus aureus IID 1 77 (MRSA)
- test solution A 0.1 -mL portion of the cell suspension was inoculated to 10 mL of 3 % sample solution (prepared with purified water), and this solution was called the test solution. Then, the test solution was stored at room temperature. After 30 minutes, it was immediately diluted by 10-fold [for the test strains (b)], by 100-fold [for the test strain (a)] and by 1000-fold [for the test strains (c) to (e)] with SCDLP broth (Nihon Pharmaceutical Co. Ltd.). After 6 hours, it was diluted in a similar way. Then, the viable cell counts of the test solutions were measured at each time. As controls, purified water and physiological saline [only for the test strain (e)] were prepared in the same manner. The viable cell counts of the controls were determined at the initial point, after 30 minutes and also after 6 hours.
- Suspensions of Escherichia coli, Escherichia coli (Serovar 0157. ⁇ 7, Shiga toxin I & Il-producing Escherichia coli), Listeria monocytogenes, Salmonella enterica, and Methicillin-resistant Staphylococcus aureus (MRSA) were separately inoculated to the sample (hereafter called “the test solutions") and stored at room temperature. After 30 minutes and also after 6 hours, the viable cell count of each test solution was determined. The test method for determining viable cell count was validated by a preliminary test.
- test solution should be diluted by 10-fold [for Escherichia coli (Serovar 0157:H7) and Listeria monocytogenes], and by 100-fold (for Escherichia coli, Salmonella enterica, and MRSA,) with SCDLP broth to remove the effects of the sample.
- Test strains (a) Escherichia coli NBRC 3972, (b) Escherichia coli ATCC 43895 (Serovar 0157:H7, Shiga toxin I & Il-producing Escherichia coli), (c) Listeria monocytogenes VTU 206, (d) Salmonella enterica subsp. enterica NBRC 3313, (e) Staphylococcus aureus IID 1677 (MRSA)
- test solution A 0.1 -mL portion of the cell suspension was inoculated to 10 mL of 1 % sample solution (prepared with purified water), and this solution was called the test solution. Then, the test solution was stored at room temperature. After 30 minutes, it was immediately diluted by 10-fold [for the test strains (b) and (c)], and by 100-fold [for the test strain (a), (d) and (e)] with SCDLP broth (Nihon Pharmaceutical Co.. Ltd.). After 6 hours, it was diluted in a similar way. Then, the viable cell counts of the test solutions were measured at each time. As controls, purified water and physiological saline [only for the test strain (e)] were prepared in the same manner. The viable cell counts of the controls were determined at the initial point, after 30 minutes and also after 6 hours.
- test solution (1) A 1 % water solution of the sample was used as the test solution (1) and a 3 % water solution of the sample was used as the test solution (2).
- test solution (2) A 1 % water solution of the sample was used as the test solution (1) and a 3 % water solution of the sample was used as the test solution (2).
- the gas removal effects of the test solutions and control (water alone) were evaluated using formaldehyde by gas detector tube method.
- Reagents and apparatus Film bag (25 cm x 40 cm. ARAM Corporation), Formaldehyde: generated from formaldehyde (36 %, special grade. Kanio Chemical Co., Inc.) and Gas detector tube (Gastec Corporation).
- test solutions The sample weighing 0.5 g was dissolved and filled up to 50 niL with water to make I % water solution. The solution obtained was used as the test solution (1). Similarly 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution
- test solutions and control water alone were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
- Reagents and apparatus Film bag (25 cm x 40 cm. ARAM Corporation), Acetaldehyde: generated from acetaldehyde (first grade. Wako Pure Chemical Industries, Ltd.) and Gas detector tube (Gastec Corporation).
- test solution (2) Preparation of test solutions: The sample weighing 0.5 g was dissolved and filled up to 50 mL with water to make 1 % water solution. The solution obtained was used as the test solution (1). Similarly, 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution (2).
- test solutions and control water alone were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
- Table 27 shows the test conditions.
- test solution (1) A 1 % water solution of the sample was used as the test solution (1), and a 3 % water solution of the sample was used as the test solution (2).
- test solution (2) A 1 % water solution of the sample was used as the test solution (1), and a 3 % water solution of the sample was used as the test solution (2).
- the odor removal effects of the test solutions and control (water alone) were evaluated using ammonia by gas detector tube method.
- test solution The sample weighing 0.5 g was dissolved and filled up to 50 mL with water to make 1 % water solution. The solution obtained was used as the test solution (1). Similarly, 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution • (2) ⁇
- test solutions and control water alone were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
- Table 29 shows the test conditions.
- the present disclosure provides a composition for environmental clarification which has high dissolving capability.
- the present disclosure enhances the improved safety and stability. 3.
- the present disclosure also provides a composition for environmental clarification with high absorption efficiency in a cost effective way.
- the present disclosure further reacts even with slightly visible ray.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Environmental & Geological Engineering (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Catalysts (AREA)
- Physical Water Treatments (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The present disclosure provides a composition for environmental clarification comprising: a photocatalyst; a redox agent; an absorbent; a stabilizing agent; and water, wherein photocatalyst is coated with apatite. The present disclosure further relates to a process for producing a composition for environmental clarification.
Description
TECHNICAL FIELD
[0001] The present disclosure relates to a composition which is used as an environmental purification material. The present disclosure further relates to a process for producing the composition.
BACKGROUND
[0002] An absorbent or an acid or alkali solution has been widely used in many fields for preventing or removing malodors or for removing harmful substances in the air. One major problem associated with this method is the treatment of the waste solution or the adsorbent utilized, which may cause secondary pollution. A method to hide unpleasant odors by using a perfume may also be used, but there is a possibility that the odor of the perfume gets transferred to the food materials or substances and hence resulting in damage to the food by the smell of the perfume itself.
[0003] Further, organic chemical substances, particularly based on alcohols, phenols, aldehydes, carboxylic acid, esters, ethers, nitriles, peroxide-epoxides, halogens, and organometals have long been used to inhibit the proliferation of microbes. Although these chemicals provide good antibacterial and bactericidal strength, they are essentially toxic, irritate the skin, and may lead to allergies, "sickhouse syndrome", "hypersensitivity to chemical substances, etc. Therefore, care must be taken in the use of these chemicals.
[0004] US7375069 describes photocatalytic methods, compositions and kits for removal of stains such as oil, grease, paint, mold, rust and the like from solid surfaces.
[0005] EP 1437397 describes a cleaning agent comprising diamond-like carbon, or a covered component produced by partially covering the surface of diamond-like carbon with a ceramic, a thickener and an oxidant.
[0006] EP 1064999 discloses a photocatalytic powder for environmental clarification, comprising finely divided titanium dioxide having a coating of porous calcium phosphate, further calcium phosphate precipitated form pseudo substance solution consisting of sodium chloride, sodium phosphate, potassium chloride and so on.
[0007] US6180548 discloses an environment purifying material wherein porous apatite film is clotted on the surface of titanium oxide which comprises a carrier selected from
alumina, silica gel, zeolite, clay sintered. The apatite is obtained from pseudo-body fluid having composition ratio: Na+ 120 to 160 mM, HP04 2" 0.5 to 30 mM.
[0008] Therefore, there is a need of a composition for environmental clarification, and an economical process for its preparation which are safe and easy to use.
SUMMARY
[0009] The present disclosure relates to a composition comprising: a photocatalyst; a redox agent; an absorbent; a stabilizing agent, and water; wherein the photocatalyst is coated with apatite.
[0010] The present disclosure further relates to a process for producing a composition, the process comprising heating 2%-8% w/w of a photocatalyst coated with apatite in a slurry comprising at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%- 1% w/w, a stabilizing agent in the range of 20%-25% w/w, and water in the range of 0.5%- 1% v/w to obtain the composition.
[0011] The composition disclosed in the present disclosure is used as an environmental purification material by dissolving toxic materials into non-hazardous materials.
[0012] These and other features, aspects, and advantages of the present disclosure will become better understood with reference to the following description. This statement is provided to introduce a selection of concepts in simplified form. This statement is not intended to identify key features or essential features of the subject matter, nor is it intended to be used to limit the scope of the subject matter.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The above and other features, aspects, and advantages of the subject matter will be better understood with regard to the following description, appended claims, and accompanying drawings where:
[0014] Figure 1 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is formaldehyde, in accordance with an embodiment of the present disclosure.
[0015] Figure 2 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is acetaldehyde, in accordance with an embodiment of the present disclosure.
[0016] Figure 3 shows a plot of gas concentration (ppm) vs time period (h), where the testing gas is ammonia, in accordance with an embodiment of the present disclosure. DETAILED DESCRIPTION
[0017] The present invention now will be described more fully hereinafter. Indeed, the invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. As used in the specification, and in the appended claims, the singular forms "a", "an", "the", include plural referents unless the context clearly dictates otherwise.
[0018] The present disclosure is to provide a composition for environmental clarification that has high dissolving capability, high absorption efficiency, improved safety and stability, and react with visible ray having low intensity.
[0019] The present disclosure provides a composition comprising: a photocatalyst; a redox agent; an absorbent; a stabilizing agent; and water; wherein the photocatalyst is coated with apatite.
[0020] The present disclosure provides a composition comprising: a photocatalyst in the range of 2%-8% w/w; a redox agent in the range of 40%-65% w/w; an absorbent in the range of 0.5%-l% w/w; a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%-l% v/w, wherein the photocatalyst is coated with apatite.
[0021] The present disclosure provides a composition for environmental clarification comprising: 8% w/w of a photocatalyst; 65% w/w of at least one redox agent; 1 % w/w of an absorbent; 25% w/w of a stabilizing agent; and 1% v/w of water, wherein photocatalyst is coated with apatite.
[0022] The photocatalyst used in the present disclosure is a substance that absorbs light and, in doing so, catalyzes a reaction. The photocatalyst of the present disclosure is selected from the group consisting of titanium dioxide, zinc oxide, tungsten oxide, silver oxide, copper oxide, and magnesium oxide.
[0023] The preferred photocatalyst used in the present disclosure is titanium dioxide which is further coated with apatite.
[0024] Photocatalytic action results when titanium oxide is irradiated with light, an electron having a strong reducing action and a positive hole having a strong oxidizing action are generated and a molecular seed coming into contact therewith is decomposed by the oxidation-reduction action.
[0025] In accordance with the present disclosure, the average particle diameter of titanium dioxide is in the range of 20 nanometer to 500 nanometer.
[0026] The preferred average diameter of titanium dioxide is in the range of 100 nanometer to 300 nanometer.
[0027] If the average particle diameter is smaller than 20 nanometer, the efficient production is difficult to attain, whereas if the average particle diameter exceeds 500 nanometer, the performance as a photocatalyst greatly decreases.
[0028] In an embodiment, the composition is mixed with water in a range of 1 :70 to 1 : 100 w/v. The aqueous composition of the photocatalyst composition is used in the application quantity range of 0.1 -1.5 % (w/v) with water.
[0029] The apatite used in the present disclosure is selected from the group consisting of hydroxyapatite, fluorapatite, chlorapatite, and combinations thereof. The apatite of the present disclosure is a phosphate mineral used to coat the photocatalyst. The apatite of the present disclosure is in crystalline form. In general, apatite is used as a material for medical products and cosmetics, such as treatment for bone fracture and cavity.
[0030] The preferred apatite used in the present disclosure is hydroxyapatite. Hydroxyapatite is used because of safety to human body and has excellent absorbance of ammonia and aldehyde.
[0031] The photocatalyst coated with apatite can be produced by methods known in the art or can be purchased separately.
[0032] The redox reagent of the present disclosure is selected from the group consisting of citric acid, sodium percarbonate and combinations thereof. The redox reagent used in the present disclosure is a reagent that can induce an oxidation or a reduction.
[0033] In yet an embodiment of the present disclosure, the absorbent is selected from the group consisting of alumina, silica gel, zeolite, clay sintered compacts, glass and
foam ceramics. The absorbent of the present disclosure is a substance that is capable of absorbing heat, light, moisture, etc.
[0034] The preferred absorbent is silica gel. Silica gel is suitable for the coating by its transparency.
[0035] The stabilizing agent of the present disclosure is sodium acid phosphate. Stabilizing agent is used in a very small amount to avoid the deterioration of its performance.
[0036] The composition of the present disclosure has an application in form of a paste, powder or slurry, preferably in form of a powder.
[0037] The shelf life of the composition for environmental clarification of the present disclosure is 2-3 years. However, the storage conditions to maintain the performance of the composition of the present disclosure during shelf life is by avoiding moisture and direct sunlight from the composition, further avoid storage at room temperature or higher temperature.
[0038] In accordance with the present disclosure, the temperature to store the composition is less than 10°C. The preferred temperature to store the composition is less than 5°C.
[0039] The present disclosure provides a composition for environmental clarification comprising: titanium dioxide in the range of 6%-8% w/w; citric acid in the range of 20%- 30% w/w; sodium percarbonate in the range of 30%-35% w/w; silica gel in the range of 0.5%-l% w/w; sodium acid phosphate in the range of 20%-25% w/w; and water in the range of 0.5%- 1% v/w, wherein titanium dioxide is coated with apatite.
[0040] The present disclosure provides a composition for environmental clarification comprising: 8% w/w of titanium dioxide; 30% w/w of citric acid; 35% w/w of sodium percarbonate; 1% w/w of silica gel; 25% w/w of sodium acid phosphate; and 1 % w/v of water, wherein titanium dioxide is coated with apatite.
[0041] In accordance to the present disclosure, the composition for environmental clarification is active at an intensity of light in a range from 1/10 to 1/100 candela. The composition of the present disclosure reacts with visible ray having low intensity like
light emitted from electric bulbs, room light to high energy ray like sunlight and generate high dissolving capability.
[0042] A process for producing a composition, comprising heating 2%-8% of a photocatalyst coated with apatite in a slurry containing at least one redox agent, an absorbent, a stabilizing agent, and water to obtain a composition.
[0043] In an embodiment of the present disclosure, the process comprising heating 2%- 8% w/w of a photocatalyst coated with apatite in a slurry containing at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%- 1 % w/w, a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%-l% v/w to obtain a composition.
[0044] In an embodiment of the present disclosure, the process comprising heating 6%- 8% w/w of a photocatalyst coated with apatite in a slurry containing at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%-l % w/w, a stabilizing agent in the range of 20%-25% w/w; and water in the range of 0.5%- 1 % v/w in the temperature at the range of 30-40 °C for 20-26 hours to obtain a composition.
[0045] In another embodiment of the present disclosure, the process further comprises diluting the composition with water in a range of 1 : 70 to 1 : 100 w/v.
[0046] The composition disclosed in the present disclosure is used as an environmental purification material by dissolving toxic materials into non-hazardous materials like water and carbon dioxide gas. The composition for environmental clarification of the present disclosure is used to inactivate or eliminate micro-organisms, sterilize, deodorize sludge,
[0047] The advantageous effect of the composition of the present disclosure includes (1) anti bacteria and anti fungus effect: dissolve and eliminate E. coli, Legionella, influenza, viruses, fungus, and other toxicity causing microorganisms in foods, (2) deodorization: dissolve viruses, bacteria, and toxic organic materials that cause bad odor into odor-free and non-hazardous water and carbon dioxide gas, and (3) sanitization of soil and water quality: sterilize, deodorize sludge, water pollutant with anaerobes and blue-green algae.
[0048] The composition for environmental clarification of the present disclosure is applied by spray coating a 100-fold diluted solution by plating machine or by ultra sonic nebulizer.
[0049] The applicable fields for the use of composition for environmental clarification of the present disclosure include hospital/operation room, hospital/examination room, waiting room, care home, kitchen/food processing plant, hotel, restaurant, vehicle, ship airplane, residence, chicken farm, dairy farm, risk management, and contingency planning.
[0050] The composition of the present disclosure is irradiated with light to generate hydroxyl radical (OH radical), whereby hydroxyl radical (OH radical) generated results in the conversion of toxic organic materials into non-hazardous materials.
[0051] In accordance to the present disclosure, the mechanism of the composition for the purification of environment includes; irradiating the light on the composition for environmental clarification to generate hydroxyl radical (OH radical), due to the polarity of the .OH radical the dissolving capability of the composition for environmental clarification increases that results in the conversion of toxic organic materials into non- hazardous materials such as water and carbon dioxide.
EXAMPLES:
[0052] The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein.
Example 1:
[0053] The composition for environmental clarification comprises the following active ingredients:
• titanium dioxide coated with apatite in the range of 2%-8% w/w;
• citric acid and sodium percarbonate in the range of 40%-65% w/w;
• silica gel in the range of 0.5%-l% w/w;
• sodium acid phosphate in the range of 20%-25% w/w; and
• water in the range of 0.5%- 1 % v/w.
Example 2:
[0054] The composition for environmental clarification comprises the following active ingredients:
• titanium dioxide coated with apatite in the range of 6% -8% w/w;
• citric acid in the range of 20% -30% w/w;
• sodium percarbonate in the range of 30%-35% w/w;
• silica gel in the range of 0.5%- 1 % w/w;
• sodium acid phosphate in the range of 20%-25% w/w; and
• water in the range of 0.5%-l% v/w.
Example 3:
[0055] The composition for environmental clarification comprises the following active ingredients:
. · 8% w/w of titanium dioxide coated with apatite;
• 30% w/w of citric acid;
• 35% w/w of sodium percarbonate;
• 1% w/w of silica gel;
• 25% w/w of sodium acid phosphate; and
• 1 % v/w of water.
Example 4:
Preparation and storage of the composition:
[0056] 2%-8% w/w of titanium dioxide coated with apatite was heated in a slurry containing citric acid and sodium percarbonate in the range of 40%-65% w/w, silica gel in the range of 0.5%- 1 % w/w, sodium acid phosphate in the range of 20%-25% w/w and
water in the range of 0.5%-l % v/w in the temperature at the range of 36-37 °C for 24 hours to obtain a composition.
[0057] The composition was stored at temperature less than 10°C.
Example 5:
Preparation and storage of the composition:
[0058] 6%-8% w/w of titanium dioxide coated with apatite was heated in a slurry containing citric acid and sodium percarbonate in the range of 50%-65% w/w, silica gel in the range of 0.5%-l% w/w, sodium acid phosphate in the range of 20%-25% w/w and water in the range of 0.5%-l% v/w in the temperature at the range of 36-37 °C for 24 hours to obtain a composition.
[0059] The composition was stored at temperature less than 10°C.
Example 6:
Preparation and storage of the composition:
[0060] 8% w/w of titanium dioxide coated with apatite was heated in a slurry containing 65% w/w of citric acid and sodium percarbonate, 1 % w/w of silica gel, 25% w/w of sodium acid phosphate and 1% v/w of water in the temperature at the range of 36- 37 °C for 24 hours to obtain a composition
Example 7:
Comparison of activity of the composition for environmental clarification with other methods:
[0061] Table 1 describes the comparison disclosed in the present disclosure with other methods such as ozone, hypochlorous acid, chrorine dioxide. It was observed from Table 1 that the composition disclosed in the present disclosure have higher anti-bacterial activity than other known methods.
Table 1 : Comparison of the activity of the composition with other methods.
environm
ental
clarificati
on
Ozone 2.07V Good Good Hazardo Short Yes (Sterilizat us
ion and
Deodoriza
tion)
Hypochlo 1.49V Fair Fair Hazardo Short Yes rous Acid us
(Bleach &
Sterilizati
on)
Chrorine 1.36V Fair Good Rather Short Yes Dioxide Safe
(Antisepti
c)
Results based on the experiments carried out in table 2:
Table 2:
Example 8:
Preparation of Suspension Solution of the composition for environmental clarification:
[0062] The suspending solution was prepared by homogenous mixing of composition for environmental clarification in water for 1-2 hours with constant stirring. The above mixture was degassed for 1 day under an inert atmosphere. The resulting mixture was kept under constant stirring for 2-3 minutes to obtain the suspending solution of the composition for environmental clarification in water.
Example 9:
Acute Oral Toxicity Test in Female Mice:
• Preparation of test solution:
[0063] The test sample was dissolved in water to make 1 w/v% test solution. 1 w/v% test solution was diluted with water for injection to make 100 mg/mL test dilution.
• Experimental animals:
[0064] Female mice, at an age of 5 weeks were tested. Before test, they are acclimated to laboratory conditions for about 1 week to verify that no abnormalities are shown in general conditions. They were hosted in plastic cages (five animals per cage) under standard laboratory conditions (temperature 23 °C ± 2 °C, light dark cycle: 12/12 hours). Feed (Labo MR Stock diet, Nihon Nosankogyo K.K) and tap water were provided ad libitum throughout the experiment.
• Procedure:
[0065] Female mice are allocated into experimental and control groups each consisting of five mice. The mice are starved for about 4 hours before administration. After measurement of body weight, the animals in the experimental group are administered orally the test solution in a single dose using a stomach tube. The animals in the control group are administered solvent as vehicle control in the same manner. The administered volume did not exceeded 20 mL/kg of body weight (b.w). The clinical observation is carried out frequently on the day of the administration and once a day for the following 13 days. The body weight is measured after 7 and 14 days of the administration, and the mean body weight values of the experimental and control groups are statistically analyzed by t-test (a = 0.05). At the completion of the test, all of the mice are sacrificed for necropsy.
• Results:
[0066] (1) Death of animals: None of the mice died during the experimental period.
[0067] (2) Clinical observations: No abnormalities were observed in any of the mice during the experimental period.
[0068] (3) Body weight changes: The body weight changes were shown in Table 3. From the Table 3, it was observed that no significant differences in body weight were detected between the experimental and control groups.
Table 3
The values are mean ± SD.
The values in parentheses represent the number of animals.
[0069] (4) Necropsy: No remarkable changes were found in any of the mice.
• Conclusion:
[0070] The acute oral toxicity in female mice of 1 w/v% test solution was determined. Oral administration of 2000 mg/kg b.w. of the test sample caused neither anbormalities nor death in any of the mice during the observation period. Consequently, the LD50 value (single dose, oral administration) of 1 w/v% test solution is considered to be more than 2000 mg/kg b.w. in female mice.
Example 10:
Eye Irritation Test in Rabbits:
• Experimental animals
[0071] Three male Japanese white rabbits were tested. They are acclimated to laboratory conditions for more than 1 week to confirm that there are no abnormalities in general conditions. Then, they were individually housed in fiber reinforced plastic (FRP) cages under standard laboratory conditions (Temperature; 22 °C ± 2 °C, Light-dark cycle:
12/12 hours). Tap water was provided ad libitum, and a certain amount of LRC4 diet (Oriental Yeast Co., Ltd.) was provided in proportion to each animal's body weight.
• Procedure:
[0072] Both the eyes of each animal are examined on the first day of the test to ensure the absence of any ocular abnormalities. After the animals are weighed, 0.1 g / 0.1 mL of the test sample is instilled into the conjunctival sac of one eye of each animal. The lids are then gently held together for about 1 second. Similarly, water for injection, as vehicle control, was instilled into another eye. Then, the cornea, iris, and conjunctivae are observed clinically using a hand slit-lamp at 1, 24, 48 and 72 hours after the instillation. The ocular reactions are observed and scored according to the criteria of the Draize method, shown in Table 4. The corneal epithelium is examined further in detail with the use of fluorescein sodium at each observation time except for 1 hour after the instillation. Other eyes, which are not treated with the test sample, are used as controls. The total score was calculated for each animal according to the formula shown in Table 5, and the mean total score is obtained at each observation time. Eye irritation potential of 1 w/v% test sample was graded by means of the maximum mean total score on the basis of Table 6.
• Results:
[0073] After 1 hour of instillation, the test eyes of one animal (Rabbit No. 3) showed redness of palpebral and bulbar conjunctiva (both score 1). These responses, however, disappeared by the 24-hour observation. No abnormalities were found during the subsequent period. In the remaining animals, no abnormalities were found throughout the observation period.
[0074] In contrast, the control eyes of all of the animals showed no abnormalities throughout the observation period.
[0075] In addition, fluorescein staining was not seen in the test and control eyes of all of the animals.
[0076] The maximum mean total scores were 0.7 (at 1 hour after instillation) in the test eyes and 0 in the control eyes.
• Conclusion:
[0077] The test sample was tested for eye irritation potential in rabbits in accordance with OECD Guidelines for the Testing of Chemicals 405 (201 2).
[0078] A 0.1 -mL portion of 1 w/v% test solution was applied to one eye of three rabbits, and water for injection, as vehicle control, was similarly applied to another eye. As a result, in the test eyes, redness of palpebral and bulbar conjunctiva were seen in one animal at I hour after instillation. These responses, however, disappeared by the 24-hour observation. In the control eyes, no eye irritation was observed in any of the rabbits throughout the observation period. The maximum mean total scores, calculated by Draize method, were 0.7 (at 1 hour after instillation) in the test eyes and 0 in the control eyes. Consequently, 1 w/v% test solution is classified as a non-irritant to rabbit eyes.
Table 4 (1): Grades for ocular lesions
Cornea
(A) Opacity-degree of density (area most dense taken for reading)
No opacity · · ·■· 0
Scattered or diffuse area,
details of iris clearly visible 1
Easily discernible translucent areas,
details of iris slightly obscured 2
Opalescent areas, no details of iris visible,
size of pupil barely discernible 3
Opaque, iris invisible · · 4
(B) Area of cornea involved
One quarter (or less) but not zero ■· ■ · 1
Greater than one quarter, but less than half · 2
Greater than half, but less than three quarters-- 3
Greater than three quarters, up to whole area 4
[Score = A x B 5 Maximum possible—— 80]
Iris
(A) Normal ■···· ···■· 0
Folds above normal, congestion, swelling,
circumcorneal injection (any or all of these
or combination of any thereof) iris still reacting
to light (sluggish reaction is positive) 1
No reaction to light, hemorrhage, gross destruction
(any or all of these) · ■ 2
[Score = A x 5 Maximum possible 10]
Table 4 (1): Grades for ocular lesions (continued)
Conjunctivae
(A) Redness (refers to palpebral and bulbar conjunctivae excluding cornea and iris)
Vessels normal · 0
Vessels definitely injected above normal 1
•More diffuse, deeper crimson red, individual vessels not
easily discernible · 2
Diffuse beefy red 3
(B) Chemosis
No swelling · 0
Any swelling above normal (includes nictitating membrane) 1
Obvious swelling with partial eversion of lids 2
Swelling with lids about half closed 3
Swelling with lids about half closed to completely closed 4
(C) Discharge
No discharge · · 0
Any amount different from normal (does not include small
amounts observed in inner canthus of normal animals) 1
Discharge with moistening of the lids and hairs
just adjacent to lids 2
Discharge with moistening of the lids and hairs,
and considerable area around the eye
[Score = (A + B + C) x 2 Maximum po -20]
Table 5: Calculation method of the total score
A, B, and C show the scores of (A), (B), and (C) given in Table 5, respectively.
* Calculation at each observation time.
Table 6: Evaluation of eye irritation
Table 7: Body weight of the lest animals at the start of the test
Table 8: Mean total scores
Rabbit No. Total score
1 hour 24 hours 48 hours 72 hours
1 0(0) 0(0) 0(0) 0(0)
2 0(0) 0(0) 0(0) 0(0)
3 2 (0) 0(0) 0(0) 0(0)
Mean total score 0.7(0) 0 (0) 0(0) . 0(0)
The values in parentheses show the scores of the control eyes.
Table 9: Scores of irritant response in the rabbit No. I
The values in parentheses show the scores of the control eye.
— : Not recorded
Table 10: Scores of irritant response in the rabbit No. 2
Redness (A) 0(0) 0 (0) 0(0) 0(0)
(3) Conjunctivae Chemosis (B) 0(0) 0(0) 0(0) 0(0)
Discharge (C) 0(0) 0(0) 0(0) 0(0)
Score (l) = A x B x 5 0(0) 0(0) 0(0) 0(0)
Score (2) = A x 5 0(0) 0(0) 0(0) 0(0)
Score (3) = (A + B + C) * 2 0(0) 0(0) 0(0) 0(0)
Total score [(1) + (2) + (3)] 0(0) 0(0) 0(0) 0(0)
The values in parentheses show the scores of the control eye.
— : Not recorded
Table 1 1 : Scores of irritant response in the rabbit No. 3
The values in parentheses show the scores of the control eye.
— : Not recorded
Example 11:
Primary Skin Irritation Test in Rabbits:
• Preparation of test solution
[0079] The test sample is dissolved / suspended / diluted in water for injection to make 1 w/v% test solution.
• Experimental animals
[0080] Three, male Japanese white rabbits were tested. They were acclimated to laboratory conditions for more than 1 week to confirm that there are no abnormalities in general conditions. Then, they were individually housed in FRP cages under standard laboratory conditions (Temperature: 22 °C ± 2 °C, Light-dark cycle: 12/12 hours). Tap water was provided ad libitum, and a certain amount of LRC4 diet (Oriental Yeast Co., Ltd.) was provided in proportion to each animal's body weight.
• Procedure:
[0081] The back of each animal is completely shaved about 24 hours before the test, and the shaved area was divided into six sections (about 6 cm2). Two of the test sections were abraded. Abrasion was made by epidermal incision through the stratum corneum; two incisions perpendicular to the other two were made in a manner resembling a "#" pattern by use of a sterile 18-gage needle. The other two sections are left intact. A 0.5- mL portion of 1 w/v% test solutions was applied to each gauze patch (about 2 cm χ 3 cm) and held in one intact and one abraded sections on each animal with MULTI FIX-ROLL. To ensure the contact of the test solutions with skin, the patches were covered with Blenderm surgical tape. The other intact and abraded sections served as controls. After 4 hours of exposure, all the test sections are wiped with water for injection to remove the test solutions. Then, the skin reactions are read at 1 , 24, 48 and 72 hours after removal of 1 w/v% test solution according to the criteria shown in Table 12. The P.I.I, was calculated according to ISO 10993-10 Biological Evaluation of Medical Devices-Part 10 (2010). The scores of the readings at 24, 48 and 72 hours were added together and divided by 6. The mean value of three animals is regarded as P.I.I. The degree of the primary skin irritation was evaluated in accordance with the criteria shown in Table 13. The animals are weighed at the start and completion of the test.
• Results:
[0082] At 1 hour after removal, very slight erythema (score 1) was found on the intact and abraded 'skin of all of the animals. But the erythema in one animal (Rabbit No. 3) disappeared at the 24-hour observation, and the erythema in the remaining two animals (Rabbits No. 1 and 2) disappeared by the 48-hour observation. No abnormalities were found during the subsequent period. At the non-treatment intact and abraded sections, no irritation response was observed throughout the observation period. The P.1.1., calculated usinu the scores of the readings, was 0.2.
• Conclusion
[0083] The test sample was tested for primary skin irritation in rabbits in accordance with OECD Guidelines for the Testing of Chemicals 404 (2002). 1 w/v% test solution was applied occlusively for 4 hours to the intact and abraded skin. As a result, very slight erythema was found in all of the animals at 1 hour after removal, but all of the erythema disappeared within 48 hours. The primary irritation index (P.I.I.) calculated according to ISO 10993-10 Biological Evaluation of Medical Devices-Part 10 (2010) was 0.2. Consequently, the primary skin irritation of 1 w/v% test solution is considered to be negligible.
Table 12: Evaluation of skin reactions
Erythema and eschar formation
No erythema : 0
Very slight erythema (barely perceptible) · 1
Well-defined erythema 2
Moderate to severe erythema 3
Severe erythema (beet redness) to slight eschar formation
(injuries in depth) · 4*
[Total possible erythema score 4]
* Necrosis, ulcer, alopecia, scars, etc. are classified into injuries in depth, score 4.
Edema formation
No edema · 0
Very slight edema (barely perceptible) 1
Slight edema
(edges of area well-defined by definite raising) · 2
Moderate edema (raised approximately 1 mm) · 3
Severe edema (raised more than 1 mm
and extending beyond area of exposure) · 4
[Total possible edema score 4]
Irritation response categories in rabbit
Table 14: Body- weight changes (kg)
Table 15: Scores of the irritation response
Example 12:
Virus lnactivation test
• Outline of methods
[0084] The sample solution was mixed with Poliovirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test.
• , Results:
(1) Preliminary test
[0085] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 100- fold with a cell support medium.
(2) Virus infectivity assay
[0086] Table 16 shows the results.
Table 16: Virus infectivity of the mixture
Initial: TCID50 of the control at inoculation
Control: Purified water
Storage temperature: room temperature
* Logarithm of TCID5o per 1 ml, of the mixture
• Method in detail:
[0087] (1) Test virus: Poliovirus 3
10088] (2) Test cell: HEp-2 cells: HEp-2 ATCC CCL-23 (Dainippon Pharmaceutical Co. Ltd.)
[0089] (3) Culture media
a) Cell culture medium: Eagle's MEM "Nissui"(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui"(l ) including 2 % of
fetal bovine serum.
[0090] (4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5%) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[0091] 5) Test procedure: The sample was dissolved in purified water to make 0.3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 ml, of 0.3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 100-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[0092] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After removal of the culture medium, 0.1 mL of the cell support medium was added. Next, 100-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then, 0.1 mL of each dilution was poured into four wells each and cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cytopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 13:
Virus Inactivation test
• Outline of methods
[0093] The sample solution was mixed with Poliovinis suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test.
• Results:
(1 ) Preliminary test
[0094] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 100- fold with a cell support medium.
(2) Virus infectivity assay
[0095] Table 17 shows the results.
Table 17: Virus infectivity of the mixture
Initial: TCID50 of the control at inoculation
Control: Purified water
Storage temperature: room temperature
* Logarithm of TCIDso per 1 ml, of the mixture
• Method in detail:
[0096] (1 ) Test virus: Poliovirus 3
[0097] (2) Test cell: HEp-2 cells: HEp-2 ATCC CCL-23 (Dainippon Pharmaceutical Co. Ltd.)
[0098] (3) Culture media
a) Cell culture medium: Eagle's MEM "Nissui"(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui"(l) including 2 % of fetal bovine serum.
[0099] (4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[00100] 5) Test procedure: The sample was dissolved in purified water to make 0.1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 ml, of 0.1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 100-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[00101] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After removal of the culture medium, 0.1 mL of the cell support medium was added. Next, 100-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then, 0.1 mL of each dilution was poured into four wells each and cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cytopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 14:
Virus Inactivation test
• Outline of methods
[00102] The sample solution was mixed with Feline calicivirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity liters was validated by a preliminary test. Feline calicivirus is a commonly used as a surrogate for Norovirus, which can not been cultured routinely.
• Results:
(1) Preliminary test
[00103] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 10000-fold with a cell support medium.
(2) Virus infectivity assay
{00104] Table 18 shows the results.
Table 18: Virus infectivity of the mixture
Initial: TCID50 of the control at inoculation
Control: Purified water
Storage temperature: room temperature
* 1 Logarithm of TCID50per 1 ml, of the mixture
*2 Surrogate virus for Norovirus
• Method in detail:
[00105] (1) Test virus: Feline calicivims F-9 ATCC VR-782
[00106] (2) Test cell: CRFK cells (Dainippon Pharmaceutical Co., Ltd.)
[00107] (3) Culture media
a) Cell culture medium: Eagle's MEM "Nissui"(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui "(l) added 2 % of fetal bovine serum
[00108] (4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed w i th an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[00109] (5) Test procedure: The sample was dissolved in purified water to make 3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[00110] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-
contrast microscope to observe if any morphological changes (cylopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed- Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 15:
Virus Inactivation test
• Outline of methods
[00111] The sample solution was mixed with Feline calicivirus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test. Feline calicivirus is a commonly used as a surrogate for Norovirus, which can not been cultured routinely.
• Results:
( 1 ) Preliminary test
[00112] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 10000-fold with a cell support medium.
(2) Virus infectivity assay
[00113] Table 19 shows the results.
Table 19: Virus infectivity of the mixture
Initial: TCID5o of the control at inoculation
Control: Purified water
Storage temperature: room temperature
* 1 Logarithm of TCID50 per 1 ml, of the mixture
*2 Surrogate virus for Norovirus
• Method in detail:
[00114] (1) Test virus: Feline calicivims F-9 ATCC VR-782
[00115] (2) Test cell: CRFK cells (Dainippon Pharmaceutical Co., Ltd.)
[00116] (3) Culture media
a) Cell culture medium: Eagle's MEM "Nissui "(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui "(1) added 2 % of fetal bovine serum
[00117] (4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[00118] (5) Test procedure: The sample was dissolved in purified water to make 1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000- fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[00119] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold diluti on of the mixture of the sample and the virus suspension, and the control were diluted with the
cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cylopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 16:
Virus Inactivation test
• Outline of methods
[00120] The sample solution was mixed with Influenza virus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test.
• Results:
( 1 ) Preliminary test
[00121] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 10000-fold with a cell support medium.
(2) Virus infectivity assay
[00122] Table 20 shows the results.
Table 20: Virus infectivity of the mixture
TCID50: Median tissue culture infectious dose
initial: TCIDso of the control at inoculation
Control: Purified water
Storage temperature: room temperature
<4.5: Not detected
* Logarithm of TCID5o per 1 ml, of the mixture
• Method in detail:
[00123] (1) Test virus: Influenza A virus (H1N1)
[00124] (2) Test cell: MDCK (NBL-2) cells ATCC CCL-34 strain (Dainippon Pharmaceutical Co., Ltd.)
[00125] (3) Culture media
a) Cell culture medium: . Eagle's MEM "Nissui " (l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui " (l) l OOOmL
1 0% NaHCO3 1 4mL
L-glutamine (30g/L) 9.8mL l OOxvitamins for MEM 30mL
1 0% albumin 20mL
0.25 % trypsin 20mL
(4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged (3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[00126] (5) Test procedure: The sample was dissolved in purified water to make 3 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 3 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000- fold with the cell support medium, and virus infectivity was
determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[00127] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each di lution was poured into four wells each and cultured in a CO; incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cylopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 17:
Virus Inactivation test
• Outline of methods
[00128] The sample solution was mixed with Influenza virus suspension and stored at room temperature. After 30 minutes and also after 6 hours, virus infectivity titers were determined. The method of infectivity titers was validated by a preliminary test.
• Results:
( 1 ) Preliminary test
[00129] The results of the preliminary test indicated that the effects of the sample were removed by diluting the mixture of the sample solution and the virus suspension to 10000-fold with a cell support medium.
(2) Virus infectivity assay
[00130] Table 21 shows the results.
Table 21 : Virus infectivity of the mixture
TCID50: IV edian tissue culture infectious dose
Initial: TCID50 of the control at inoculation
Control: Purified water
Storage temperature: room temperature
<3.5: Not detected
* Logarithm of TCID50 per 1 ml, of the mixture
• Method in detail:
[00131 J (1) Test virus: Influenza A virus (H1N1)
[00132] (2) Test cell: MDCK (NBL-2) cells ATCC CCL-34 strain (Dainippon Pharmaceutical Co., Ltd.)
[00133J (3) Culture media
a) Cell culture medium: Eagle's MEM "Nissui "(l) (Nissui Pharmaceutical Co., Ltd.) including 10 % of fetal bovine serum
b) Cell support medium: Eagle's MEM "Nissui " (l) l OOOmL
1 0% .NaHCO3 14mL
L-glutamine (30g/L) 9.8mL 1 00 x vitamins for MEM 30mL
10% albumin 20mL
0.25 % trypsin 20mL
(4) Preparation of virus suspension
a) Cell incubation: The test cell was monolayer-cultured in a tissue culture flask using the cell culture medium.
b) Virus inoculation: After monolayer culture, the culture medium was removed from the flask, and the test virus was inoculated. Next, the cell support medium was added, and the virus was cultured in a C02 incubator (C02: 5 %) at 37 °C ± 1 °C for 1 to 5 days.
c) Preparation of virus suspension: The cell form was observed with an inverted phase-contrast microscope. After morphological changes (cytopathic effects) were confirmed, the culture solution was centrifuged
(3000 r/min, 10 minutes). The supernatant was used as a virus suspension.
[00134] (5) Test procedure: The sample was dissolved in purified water to make 1 % solution. A 0.1 -mL portion of the virus suspension was inoculated into 1 mL of 1 % sample solution and stored at room temperature. After 30 minutes and also after 6 hours, it was diluted to 10000-fold with the cell support medium, and virus infectivity was determined. As a control, purified water was prepared in the same manner as the sample. Virus infectivity was determined at the initial point, after 30 minutes, and after 6 hours.
[00135] (6) Virus infectivity assay: The test cell was monolayer-cultured in a tissue culture microplate (96-well) using the cell culture medium. After the culture medium was removed, 0.1 mL of the cell support medium was added. Next, 10000-fold dilution of the mixture of the sample and the virus suspension, and the control were diluted with the cell support medium to obtain serial 10-fold dilutions. Then 0.1 mL of each dilution was poured into four wells each and cultured in a CO; incubator (C02: 5 %) at 37 °C ± 1 °C for 4 to 7 days. After culture, the cells were observed by inverted phase-contrast microscope to observe if any morphological changes (cylopathic effects) had occurred. Then, median tissue culture infectious dose (TCID50) was calculated by Reed-Muench method and converted into virus infectivity liter per 1 mL of the mixture.
Example 18:
Antibacterial Activity test
• Outline of methods
[00136] Suspensions of Escherichia coli, Escherichia coli (Serovar 0157:H7, Shiga toxin I & Il-producing Escherichia coli), Listeria monocytogenes, Salmonella enterica, and Methicillin-resistant Staphylococcus aureus (MRSA) were separately inoculated to the sample (hereafter called "the test solutions") and stored at room temperature. After 30 minutes and also after 6 hours, the viable cell count of each test solution was determined. The test method for determining viable cell count was validated by a preliminary test.
• Results:
[00137] Table 22 shows the results.
[00138] The results of the preliminary test revealed that the test solution should be diluted by 10-fold [for Escherichia coli (Serovar 0157:H7)], by 100-fold (for Escherichia coli) and by 1000-fold (for Listeria monocytogenes, Salmonella enterica, and MRSA) with SCDLP broth to remove the effects of the sample.
Table 22: Viable counts of the lest solutions
<10, <100 and <1000: Not detected
Control: Purified water and physiological saline (only for MRSA)
Storage temperature: room temperature
* The viable count of the control immediately after inoculation was defined as the viable count at the initial point.
• Method in detail:
[00139] (1) Test strains: (a) Escherichia coli NBRC 3972, (b) Escherichia coli ATCC 43895 (Serovar 0157:H7, Shiga toxin I & 11-producing Escherichia coli), (c) Listeria monocytogenes VTU 206, (d) Salmonella enterica subsp. enterica NBRC 3313, (e) Staphylococcus aureus IID 1 77 (MRSA)
[00140] (2) Medium for determination of viable count and incubation conditions: SCDLP Agar (Nihon Pharmaceutical Co., Ltd.). Pour plate method 35 °C ± 1 °C, 2 days.
[00141] (3) Preparation of cell suspensions: The test organism was grown on Nutrient Agar (Liken Chemical Co., Ltd.) for 18 to 24 hours al 35 °C ± 1 °C. After incubation, the culture was suspended in purified water [for the test strains (a) to (d)] and in physiological saline [for the test strain (e)[ to contain about 107 to 108 cells/mL. The obtained suspensions were used as cell suspensions.
[00142] (4) Test procedure: A 0.1 -mL portion of the cell suspension was inoculated to 10 mL of 3 % sample solution (prepared with purified water), and this solution was called the test solution. Then, the test solution was stored at room temperature. After 30 minutes, it was immediately diluted by 10-fold [for the test strains (b)], by 100-fold [for the test strain (a)] and by 1000-fold [for the test strains (c) to (e)] with SCDLP broth (Nihon Pharmaceutical Co. Ltd.). After 6 hours, it was diluted in a similar way. Then, the viable cell counts of the test solutions were measured at each time. As controls, purified water and physiological saline [only for the test strain (e)] were prepared in the same manner. The viable cell counts of the controls were determined at the initial point, after 30 minutes and also after 6 hours.
Example 19:
Antibacterial Activity test
• Outline of methods
[00143] Suspensions of Escherichia coli, Escherichia coli (Serovar 0157.Ή7, Shiga toxin I & Il-producing Escherichia coli), Listeria monocytogenes, Salmonella enterica, and Methicillin-resistant Staphylococcus aureus (MRSA) were separately inoculated to the sample (hereafter called "the test solutions") and stored at room temperature. After 30 minutes and also after 6 hours, the viable cell count of each test solution was determined. The test method for determining viable cell count was validated by a preliminary test.
• Results:
[00144] Table 23 shows the results.
[00145] The results of the preliminary test revealed that the test solution should be diluted by 10-fold [for Escherichia coli (Serovar 0157:H7) and Listeria monocytogenes],
and by 100-fold (for Escherichia coli, Salmonella enterica, and MRSA,) with SCDLP broth to remove the effects of the sample.
Table 23: Viable counts of the lest solutions
<10, and <100: Not detected
Control: Purified water and physiological saline (only for MRSA)
Storage temperature: room temperature
* The viable count of the control immediately after inoculation was defined as the viable count at the initial point.
• Method in detail:
[00146] (1) Test strains: (a) Escherichia coli NBRC 3972, (b) Escherichia coli ATCC 43895 (Serovar 0157:H7, Shiga toxin I & Il-producing Escherichia coli), (c) Listeria monocytogenes VTU 206, (d) Salmonella enterica subsp. enterica NBRC 3313, (e) Staphylococcus aureus IID 1677 (MRSA)
[00147] (2) Medium for determination of viable count and incubation conditions: SCDLP Agar (Nihon Pharmaceutical Co., Ltd.). Pour plate method 35 °C ± 1°C, 2 days.
[00148] (3) Preparation of cell suspensions: The test organism was grown on Nutrient Agar (Liken Chemical Co., Ltd.) for 18 to 24 hours al 35 °C ± 1 °C. After incubation, the
culture was suspended in purified water [for the test strains (a) to (d)] and in physiological saline [for the test strain (e)] to contain about 107 to 108 cells/mL. The obtained suspensions were used as cell suspensions.
[00149] (4) Test procedure: A 0.1 -mL portion of the cell suspension was inoculated to 10 mL of 1 % sample solution (prepared with purified water), and this solution was called the test solution. Then, the test solution was stored at room temperature. After 30 minutes, it was immediately diluted by 10-fold [for the test strains (b) and (c)], and by 100-fold [for the test strain (a), (d) and (e)] with SCDLP broth (Nihon Pharmaceutical Co.. Ltd.). After 6 hours, it was diluted in a similar way. Then, the viable cell counts of the test solutions were measured at each time. As controls, purified water and physiological saline [only for the test strain (e)] were prepared in the same manner. The viable cell counts of the controls were determined at the initial point, after 30 minutes and also after 6 hours.
Example 20:
Gas removal effect test
• Outline of methods
[00150] A 1 % water solution of the sample was used as the test solution (1) and a 3 % water solution of the sample was used as the test solution (2). The gas removal effects of the test solutions and control (water alone) were evaluated using formaldehyde by gas detector tube method.
• Results:
[00151] Table 24 and figure 1 shows the test results.
Table 24 Test results (Testing gas: formaldehyde)
Initial gas concentration: about 20 ppm • Method in detail:
[00152] (1) Reagents and apparatus: Film bag (25 cm x 40 cm. ARAM Corporation), Formaldehyde: generated from formaldehyde (36 %, special grade. Kanio Chemical Co., Inc.) and Gas detector tube (Gastec Corporation).
[00153] (2) Preparation of test solutions: The sample weighing 0.5 g was dissolved and filled up to 50 niL with water to make I % water solution. The solution obtained was used as the test solution (1). Similarly 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution
(2)·
[00154] (3) Procedures: The test solutions and control (water alone) were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
[00155] Table 25 shows the test conditions
Table 25: Test conditions
Example 21:
Odor removal effect test
• Outline of methods
[00156] A 1 % water solution of the sample was used as the test solution (1), and a 3 % water solution of the sample was used as the test solution (2). The odor removal effects of the test solutions and control (water alone) were evaluated using acetaldehyde by gas detector tube method.
• Results:
[00157] Table 26 and figure 2 shows the test results.
Table 26: Test results (testing gas: acetaldehyde)
Unit: ppm
Initial gas concentration: about 20 ppm • Method in detail:
[00158] (1) Reagents and apparatus: Film bag (25 cm x 40 cm. ARAM Corporation), Acetaldehyde: generated from acetaldehyde (first grade. Wako Pure Chemical Industries, Ltd.) and Gas detector tube (Gastec Corporation).
[00159] (2) Preparation of test solutions: The sample weighing 0.5 g was dissolved and filled up to 50 mL with water to make 1 % water solution. The solution obtained was used as the test solution (1). Similarly, 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution (2).
[00160] (3) Procedures: The test solutions and control (water alone) were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each
determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
[00161] Table 27 shows the test conditions.
Table 27: Test conditions
Example 22:
Odor removal effect test
• Outline of methods
[00162] A 1 % water solution of the sample was used as the test solution (1), and a 3 % water solution of the sample was used as the test solution (2). The odor removal effects of the test solutions and control (water alone) were evaluated using ammonia by gas detector tube method.
• Results:
[00163] Table 28 and figure 3 show the test results.
Table 28: Test results (testing gas: ammonia)
Unit: ppm
Initial gas concentration: about 100 ppm • Method in detail:
[00164] (1) Reagents and apparatus: Film bag (25 cm x 40 cm, ARAM Corporation), Ammonia: generated from ammonia water (28 %, special grade. Koso Chemical Co.. Ltd.) and Gas detector tube (Gastec Corporation).
[00165] (2) Preparation of test solutions: The sample weighing 0.5 g was dissolved and filled up to 50 mL with water to make 1 % water solution. The solution obtained was used as the test solution (1). Similarly, 1.5 g of the sample was dissolved and filled up to 50 mL to make 3 % water solution. The solution obtained was used as the test solution • (2)·
[00166] (3) Procedures: The test solutions and control (water alone) were put in film bags. After the bags were heat-sealed, 3 L of air was injected into the bags. Next, the testing gas was added to a specified concentration, and the bags were allowed to stand at room temperature. Then, the gas concentrations in the bags were determined at each determination time. In addition, the testing gas alone (without the test solutions or water) was prepared in the same manner as a blank test.
[00167] Table 29 shows the test conditions.
Table 29: Test conditions
Advantages:
[00168] The previously described versions of the subject matter and its equivalent thereof have many advantages, including those which are described below:
1. The present disclosure provides a composition for environmental clarification which has high dissolving capability.
2. The present disclosure enhances the improved safety and stability.
3. The present disclosure also provides a composition for environmental clarification with high absorption efficiency in a cost effective way.
4. The present disclosure further reacts even with slightly visible ray.
[00169] Although the subject matter has been described in considerable detail with reference to certain preferred embodiments thereof, other embodiments are possible. As such, the spirit and scope of the disclosure should not be limited to the description of the preferred embodiment contained therein.
Claims
1. A composition comprising:
a photocatalyst;
a redox agent;
an absorbent;
a stabilizing agent; and
water
wherein the photocatalyst is coated with apatite.
2. The composition as claimed in claim 1 , wherein the composition comprises:
a photocatalyst in the range of 2%-8% w/w;
at least one redox agent in the range of 40%-65% w/w;
an absorbent in the range of 0.5%-l % w/w;
a stabilizing agent in the range of 20%-25% w/w; and
water in the range of 0.5%- 1% v/w
wherein photocatalyst is coated with apatite.
3. The composition as claimed in claim 1 , wherein the composition comprises:
8% w/w of a photocatalyst;
65% w/w of at least one redox agent;
1% w/w of an absorbent;
25% w/w of a stabilizing agent; and
1 % v/w of water,
wherein photocatalyst is coated with apatite
4. The composition as claimed in claim 1 , wherein the apatite is selected from the group consisting of hydroxyapatite, fluorapatite, chlorapatite, and combinations thereof, preferably hydroxyapatite.
5. The composition as claimed in claim 1, wherein the photocatalyst is selected from the group consisting of titanium dioxide, zinc oxide, tungsten oxide, silver oxide, copper oxide and magnesium oxide, preferably titanium dioxide.
6. The composition as claimed in claim 1 , wherein the redox agent is selected from the group consisting of citric acid, sodium percarbonate and combinations thereof.
7. The composition as claimed in claim 1, wherein the absorbent is selected from the group consisting of alumina, silica gel, zeolite, clay sintered compacts, glass, foam ceramics silica, and combinations thereof.
8. The composition as claimed in claim 1 , wherein the stabilizing agent is sodium acid phosphate.
9. The composition as claimed in claim 1, wherein the composition is a powder, paste or slurry.
10. The composition as claimed in claim 1 , wherein the composition comprises:
titanium dioxide in the range of 6%-8% w/w;
citric acid in the range of 20%-30% w/w;
sodium percarbonate in the range of 30%-35% w/w;
silica gel in the range of 0.5%- 1 % w/w;
sodium acid phosphate in the range of 20%-25% w/w; and
water in the range of 0.5%- 1 % v/w.
wherein titanium dioxide is coated with apatite.
1 1. The composition as claimed in claim 1 is used as an environmental purification material by dissolving toxic materials into non-hazardous materials.
12. The composition as claimed in claim 1 , wherein the composition is mixed with water in a range of 1 : 70 to 1 : 100 w/v.
13. A process for producing a composition as claimed in claim 1, the process comprising heating 2%-8% w/w of a photocatalyst coated with apatite in a slurry containing at least one redox agent in the range of 40%-65% w/w, an absorbent in the range of 0.5%-l% w/w, a stabilizing agent in the range of 20%-25% w/w and water in the range of 0.5%- 1% v/w to obtain the composition.
14. The process as claimed in claim 13, wherein the composition is mixed with water in a range of 1 :70 to 1 : 100 w/v.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2107MU2013 IN2013MU02107A (en) | 2013-06-21 | 2013-06-21 | |
IN2107/MUM/2013 | 2013-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014203048A1 true WO2014203048A1 (en) | 2014-12-24 |
WO2014203048A9 WO2014203048A9 (en) | 2015-11-26 |
Family
ID=50439423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/000299 WO2014203048A1 (en) | 2013-06-21 | 2014-03-12 | Photocatalytic composition for environmental purification and method thereof |
Country Status (2)
Country | Link |
---|---|
IN (1) | IN2013MU02107A (en) |
WO (1) | WO2014203048A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106475097A (en) * | 2015-08-27 | 2017-03-08 | 福特环球技术公司 | SCR catalyst for the reduction of nitrogen oxides at high temperature |
CN106732793A (en) * | 2017-01-18 | 2017-05-31 | 浙江理工大学 | A kind of photocatalysis composite membrane material and preparation method thereof |
CN109603532A (en) * | 2019-01-10 | 2019-04-12 | 上海滢晶环保科技有限公司 | A kind of composite spraying agent and preparation method thereof of decomposing formaldehyde benzene homologues TVOC |
CN113351007A (en) * | 2021-06-10 | 2021-09-07 | 河北福赛生物科技发展有限公司 | Lasting biological enzyme formaldehyde scavenger |
CN113995881A (en) * | 2021-12-10 | 2022-02-01 | 上海榕婷电子设备有限公司 | Disinfection and sterilization lamp |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106799254B (en) * | 2016-12-23 | 2019-05-14 | 同济大学 | A kind of nanometer of Cu2O/Ag/TiO2The preparation method of zeolite compound photocatalyst |
CN106853373B (en) * | 2016-12-23 | 2019-05-14 | 同济大学 | A kind of nanometer of Cu2O/Ag/TiO2The preparation method of iron modified zeolite composite photo-catalyst |
CN106669767B (en) * | 2016-12-23 | 2019-05-14 | 同济大学 | Nanometer Cu2O/Ag/TiO2The preparation method of zeolite hybridization mesoporous molecular sieve composite material |
CN108554436B (en) * | 2018-05-14 | 2021-04-06 | 青岛科技大学 | Assembling of N-Ag-TiO2Application of-ZnO nano cage in methyl yellow degradation reaction under visible light |
CN108772062A (en) * | 2018-06-01 | 2018-11-09 | 湘潭大学 | A kind of ZnO/Ag2O optic catalytic composite materials and preparation method thereof and application thereof |
CN109351142A (en) * | 2018-10-09 | 2019-02-19 | 秦皇岛美博士新型材料科技有限公司 | A kind of sterilizing deodoring agent and preparation method thereof |
CN109876644A (en) * | 2019-02-18 | 2019-06-14 | 王玉廷 | A kind of biological deodorant and the preparation method and application thereof |
CN109794154A (en) * | 2019-03-19 | 2019-05-24 | 上海延龙环保科技有限公司 | Car disappears aldehyde material and preparation method |
CN110480782A (en) * | 2019-08-19 | 2019-11-22 | 舍用环境科技(宁波)有限公司 | A kind of environment protection type sheet material eliminating smell agent and preparation method thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1064999A1 (en) | 1997-12-25 | 2001-01-03 | JAPAN as Represented by DIRECTOR GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY | Photocatalyst powder for environmental purification, polymer composition containing the powder and molded article thereof, and processes for producing these |
US6180548B1 (en) | 1997-03-03 | 2001-01-30 | Agency Of Industrial Science And Technology | Environment-purifying material and its manufacturing method |
JP2003252713A (en) * | 2002-02-27 | 2003-09-10 | National Institute Of Advanced Industrial & Technology | Agent for bath liquid |
JP2003321334A (en) * | 2002-02-27 | 2003-11-11 | National Institute Of Advanced Industrial & Technology | Cleanser for false tooth with ultraviolet and visible light-active catalyst |
JP2003334454A (en) * | 2002-02-27 | 2003-11-25 | National Institute Of Advanced Industrial & Technology | Ultraviolet/visible light-sensitive catalyst |
EP1437397A1 (en) | 2001-09-27 | 2004-07-14 | National Institute of Advanced Industrial Science and Technology | Cleaning agent, antibacterial material, environment clarifying material, functional adsorbent |
US20070031461A1 (en) * | 2005-08-04 | 2007-02-08 | National Science And Technology Development Agency | An antimicrobial composition for topical application and a method thereof |
US7375069B2 (en) | 2005-06-03 | 2008-05-20 | Research Foundation Of The University Of Central Florida | Method for masking and removing stains from rugged solid surfaces |
JP2010095497A (en) * | 2008-10-20 | 2010-04-30 | Shoichi Nakamura | Bath preparation |
-
2013
- 2013-06-21 IN IN2107MU2013 patent/IN2013MU02107A/en unknown
-
2014
- 2014-03-12 WO PCT/IB2014/000299 patent/WO2014203048A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180548B1 (en) | 1997-03-03 | 2001-01-30 | Agency Of Industrial Science And Technology | Environment-purifying material and its manufacturing method |
EP1064999A1 (en) | 1997-12-25 | 2001-01-03 | JAPAN as Represented by DIRECTOR GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY | Photocatalyst powder for environmental purification, polymer composition containing the powder and molded article thereof, and processes for producing these |
EP1437397A1 (en) | 2001-09-27 | 2004-07-14 | National Institute of Advanced Industrial Science and Technology | Cleaning agent, antibacterial material, environment clarifying material, functional adsorbent |
US20040245496A1 (en) * | 2001-09-27 | 2004-12-09 | Hiroshi Taoda | Cleaning agent, antibacterial material, environment clarifying material, functional adsorbent |
JP2003252713A (en) * | 2002-02-27 | 2003-09-10 | National Institute Of Advanced Industrial & Technology | Agent for bath liquid |
JP2003321334A (en) * | 2002-02-27 | 2003-11-11 | National Institute Of Advanced Industrial & Technology | Cleanser for false tooth with ultraviolet and visible light-active catalyst |
JP2003334454A (en) * | 2002-02-27 | 2003-11-25 | National Institute Of Advanced Industrial & Technology | Ultraviolet/visible light-sensitive catalyst |
US7375069B2 (en) | 2005-06-03 | 2008-05-20 | Research Foundation Of The University Of Central Florida | Method for masking and removing stains from rugged solid surfaces |
US20070031461A1 (en) * | 2005-08-04 | 2007-02-08 | National Science And Technology Development Agency | An antimicrobial composition for topical application and a method thereof |
JP2010095497A (en) * | 2008-10-20 | 2010-04-30 | Shoichi Nakamura | Bath preparation |
Non-Patent Citations (2)
Title |
---|
"OECD Guidelines for the Testing of Chemicals", 2002, pages: 404 |
"OECD Guidelines for the Testing of Chemicals", 2012, pages: 405 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106475097A (en) * | 2015-08-27 | 2017-03-08 | 福特环球技术公司 | SCR catalyst for the reduction of nitrogen oxides at high temperature |
CN106732793A (en) * | 2017-01-18 | 2017-05-31 | 浙江理工大学 | A kind of photocatalysis composite membrane material and preparation method thereof |
CN109603532A (en) * | 2019-01-10 | 2019-04-12 | 上海滢晶环保科技有限公司 | A kind of composite spraying agent and preparation method thereof of decomposing formaldehyde benzene homologues TVOC |
CN113351007A (en) * | 2021-06-10 | 2021-09-07 | 河北福赛生物科技发展有限公司 | Lasting biological enzyme formaldehyde scavenger |
CN113995881A (en) * | 2021-12-10 | 2022-02-01 | 上海榕婷电子设备有限公司 | Disinfection and sterilization lamp |
Also Published As
Publication number | Publication date |
---|---|
IN2013MU02107A (en) | 2015-06-05 |
WO2014203048A9 (en) | 2015-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014203048A1 (en) | Photocatalytic composition for environmental purification and method thereof | |
Kangwansupamonkon et al. | Antibacterial effect of apatite-coated titanium dioxide for textiles applications | |
US10172361B2 (en) | Doped metal oxide nanoparticles of and uses thereof | |
EP0835655B1 (en) | Antibacterial/bactericidal/antiseptic agent, dermatologic preparation, and detergent composition | |
CN106342946B (en) | A kind of air purifying and sterilizing agent and preparation method | |
Zhang et al. | Ionic silver-infused peroxidase-like metal–organic frameworks as versatile “antibiotic” for enhanced bacterial elimination | |
CN102847193B (en) | Chitosan fluid dressing film | |
CA2624274A1 (en) | Silver/water, silver gels and silver-based compositions; and methods for making and using the same | |
TW201505639A (en) | Antimicrobial compositions and methods of making the same | |
EP3012225A1 (en) | Nanoparticulate titanium dioxide nanomaterial modified with functional groups and with citric extracts adsorbed on the surface, for the removal of a wide range of microorganisms | |
RU2524635C2 (en) | Antimicrobial/antibacterial medical devices, coated with traditional preparations of chinese medicine | |
KR20100031468A (en) | Anti-bacterium deodorant | |
Steckiewicz et al. | Shape-depended biological properties of Ag 3 PO 4 microparticles: evaluation of antimicrobial properties and cytotoxicity in in vitro model—safety assessment of potential clinical usage | |
JP5902672B2 (en) | Liquid form composition for maintaining contact lenses and medical materials | |
JP4366528B2 (en) | Indoor disinfection method | |
Ibrahim et al. | Antibacterial activity of silver nanoparticles synthesized by Cinnamon zeylanicum bark extract against Staphylococcus aureus | |
JP2022034488A (en) | Friction protective material composition and method for producing the same, and friction protective film obtained using the same | |
JP2021186812A (en) | Disinfectant, disinfection method and disinfection kit | |
JP7036334B1 (en) | Stabilized silver ionized water, stabilized silver ionized water production method, silver ion gel and silver ion cleaning agent | |
Avram et al. | Antibacterial effect of hydroxyapatite and silver | |
KR20060079388A (en) | The synthesis of nano inorganic antiviral agent that is effective against sars corona virus and influenza virus | |
KR20030008048A (en) | Disposable diaper comprising antibacterial and deodorizing agent | |
Kamel et al. | Approaches for development of new Nano-silver printing ink | |
Wang | Nanosized selenium: a novel platform technology to prevent bacterial infections | |
Khatoon | Silver nanocomposite material as antibacterial coating on indwelling medical devices-based biomaterials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14715406 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14715406 Country of ref document: EP Kind code of ref document: A1 |